Efficacy, Tolerability and Safety of New or Repurposed Drugs Against Lassa Fever in West African Countries
Lassa fever (LF) is a viral haemorrhagic fever responsible of 5000 deaths per year in West Africa, with in-hospital mortality at 12%. Transmission to humans occurs mainly via direct or indirect exposure to excreta from the rodent reservoir, mainly made up of Mastomys natalensis . Less frequently, LASV may also be transmitted from human to human and cause nosocomial outbreaks. Ribavirin is the only treatment available with worrying toxicity, questionable efficacy and low access because of its high cost. Consequently, there is an urgent need for new drugs to treat LF patients. The Research and Development (R&D) Blueprint of the World Health Organization (WHO) has included LF in the list of priority diseases for urgent research and development.
The INTEGRATE consortium is an unprecedented international collaboration on Lassa fever of 15 partners from 10 countries across West Africa, Europe and North America and across several disciplines (epidemiological researchers, social scientists, medical health facility professionals, humanitarian actors, etc.).
Immune Response to a Delayed Second Dose of Oral Cholera Vaccine
Immune response to a delayed second dose of oral cholera vaccine
A randomized, controlled, non-inferiority immunogenicity trial in Conakry, The Republic of Guinea
Prognostication of Oxygen Requirement in Non-severe SARS-CoV-2 Infection
Note that this is a study that is co-sponsored by Medecins Sans Frontieres, Spain, and the University of Oxford.
The primary objective of this study is to identify clinical and biochemical prognostic markers in adults with virologically confirmed COVID-19 who do not require oxygen supplementation, with a focus on: aiding safe discharge from a healthcare facility (i.e. a high NPV); near-term impact on COVID-19 interventions in resource-limited settings (i.e. simple clinico-demographic variables and biochemical markers for which near-patient / POCTs are commercially available or in late-stage development).
The secondary objective of this study is to evaluate the field-based performance of near-patient lateral flow assays for suPAR and IL-6 in adults with non-severe SARS-CoV-2 infection
100 Clinical Results associated with Médecins Sans Frontières (Belgium)
0 Patents (Medical) associated with Médecins Sans Frontières (Belgium)
100 Deals associated with Médecins Sans Frontières (Belgium)
100 Translational Medicine associated with Médecins Sans Frontières (Belgium)